NET – Incidental Findings: Small, Silent and Innocent? Abstract #1866

Introduction: Neuroendocrine tumours (NETs) are rare neoplasms, with an overall incidence of 2 cases per 100,000 individuals per year. This number is increasing due to improved diagnosis, classification and higher imaging sensitivity, which lead to discovering of small and clinically insignificant NETs.
Aim(s): Assess treatment approach after incidentally diagnosed NET.
Materials and methods: Retrospective, descriptive study of patients incidentally diagnosed with NET in our institution between April 2012 and December 2016.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Marisa Peralta Ferreira
Keywords: NET, incidentaloma

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#2278 Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?
Introduction: The annual incidence of pancreatic neuroendocrine tumours (PanNET) has been estimated to be around 0.8/100,000 inhabitants.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Fabio Giannone
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET
#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, ...